The study, published in Genes & Diseases, shows that AC004854.2 is markedly upregulated in colorectal cancer samples and tracks with worse patient outcomes. Across independent cohorts, higher expression aligns with reduced overall survival, suggesting that AC004854.2 could serve as a clinically useful prognostic indicator.

At the mechanistic level, the work connects AC004854.2 to the transcriptional control of c-MYC, a central driver of oncogenic programs. Using RNA-protein interaction approaches, the authors demonstrate that AC004854.2 directly binds the RNA-binding protein PUF60. This interaction competitively disrupts a repressive PUF60–FUBP1 complex that normally limits c-MYC transcription from a far-upstream element (FUSE) region in the c-MYC promoter.

When the restraint is removed, c-MYC transcription rises and propagates downstream cell-cycle signaling. The resulting increase in targets such as CCND2 and CDK4 helps explain why tumor cells advance through proliferation-associated checkpoints more efficiently.

Functional assays reinforce the molecular story. In cell-based experiments, forced AC004854.2 expression boosts viability and DNA synthesis, enhances colony formation, reduces apoptosis, and shifts flow-cytometry readouts toward decreased G1-phase arrest. Together, these effects point to a coordinated survival-and-growth phenotype.

The authors also report stronger malignant behavior beyond growth. Migration and invasion assays, including wound-healing and transwell-based approaches with Matrigel, indicate that AC004854.2 enhances motility and invasive capability, consistent with metastatic potential.

To test therapeutic relevance, the team employs IZCZ-3, a selective c-MYC inhibitor. Importantly, AC004854.2-driven tumor-promoting effects are substantially attenuated by IZCZ-3, establishing that the oncogenic impact depends heavily on c-MYC signaling rather than independent pathways alone.

Collectively, the study positions AC004854.2 as a master regulator that reshapes c-MYC transcription by dismantling the PUF60–FUBP1 repression axis. By revealing an upstream promoter activator, SOX4, that increases AC004854.2 expression, the findings integrate transcription factor control, RNA-mediated regulation, and oncogene activation into a single actionable mechanism.

Subject of Research: Colorectal cancer progression via AC004854.2-driven c-MYC activation
Article Title: SOX4-activated lncRNA AC004854.2 promotes colorectal cancer progression by disrupting the PUF60–FUBP1 complex and activating c-MYC transcription
News Publication Date: 2026 (exact date not provided in the provided content)
Web References: http://dx.doi.org/10.1016/j.gendis.2026.102137
References: 10.1016/j.gendis.2026.102137
Image Credits: Credit: Yanjie Chen, Rui Wang, Dexiang Zhu, Lisha Cheng, Ji Zhao, Xiguo, Li Liang, Tianshu Liu
Keywords: colorectal cancer; AC004854.2; c-MYC; PUF60; FUBP1; SOX4; lncRNA; biomarkers; apoptosis; cell cycle; migration; invasion